| Cell line name |
IGROV(CDDP) |
|---|
| Synonyms |
IGROVCDDP |
|---|
| Accession |
CVCL_C1M7 |
|---|
| Resource Identification Initiative |
To cite this cell line use: IGROV(CDDP) (RRID:CVCL_C1M7) |
|---|
| Comments |
Population: Caucasian.
Doubling time: 26 hours (PubMed=9488600).
Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
Derived from site: In situ; Ovary; UBERON=UBERON_0000992. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); ClinVar=VCV002724056; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
|
|---|
| Disease |
Ovarian endometrioid adenocarcinoma (NCIt: C7979)
Endometrioid carcinoma of ovary (ORDO: Orphanet_454723) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_1304 (IGROV-1) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
47Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=9443634; DOI=10.1007/s002800050727
Ma J.-G., Maliepaard M., Kolker H.J., Verweij J., Schellens J.H.M.
Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
Cancer Chemother. Pharmacol. 41:186-192(1998) PubMed=9488600; DOI=10.1007/s002800050744
Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G., Schellens J.H.M.
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Cancer Chemother. Pharmacol. 41:307-316(1998) PubMed=22792399; DOI=10.1371/journal.pone.0040717; PMCID=PMC3394717
Stordal B., Hamon M., McEneaney V., Roche S., Gillet J.-P., O'Leary J.J., Gottesman M.M., Clynes M.
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
PLoS ONE 7:E40717-E40717(2012) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_C1M7
|
|---|
| Encyclopedic resources |
Wikidata; Q114311715
|
|---|
| Entry history |
|---|
| Entry creation | 22-Sep-2022 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 6 |
|---|
